C9300 HCPCS code: Injection, indigotindisulfonate sodium, 1 mg
C9300 is the HCPCS Level II code for injection, indigotindisulfonate sodium, 1 mg. CMS terminated C9300 on 2025-06-30; do not bill it for later dates of service. Its Medicare coverage code is D (Special coverage instructions apply): May be covered when national or local coverage criteria are met.
Code details
| Field | Value |
|---|---|
| Section | C codes — Outpatient PPS (hospital outpatient temporary codes) |
| Coverage code | D — Special coverage instructions apply |
| Pricing indicator | 53 |
| BETOS category | O1E — Other drugs |
| Added | 2025-04-01 |
| Last action effective | 2025-07-01 |
| Terminated | 2025-06-30 |
What changed for C9300
- April 2025: Code appears in this HCPCS release
- 2025-04-01: C9300 added to HCPCS Level II
- Next scheduled CMS quarterly update (HCPCS and DMEPOS fee schedule): 2027-01-01
Frequently asked questions
What is HCPCS code C9300?
C9300 is the HCPCS Level II code for injection, indigotindisulfonate sodium, 1 mg. Short descriptor: "Indigotindisulfonate, 1 mg".
Does Medicare cover C9300?
Coverage code D — Special coverage instructions apply. May be covered when national or local coverage criteria are met.
Related C93 codes
- C9301 — Obecabtagene autoleucel, up to 400 million cd19 car-positive viable t cells, including leukapheresis and dose preparation procedures, per therapeutic dose
- C9302 — Injection, zanidatamab-hrii, 2 mg
- C9303 — Injection, zolbetuximab-clzb, 1 mg
- C9304 — Injection, marstacimab-hncq, 0.5 mg
- C9305 — Injection, nipocalimab-aahu, 3 mg
- C9306 — Injection, telisotuzumab vedotin-tllv, 1 mg
- C9307 — Injection, linvoseltamab-gcpt, 1 mg
- C9308 — Injection, carboplatin (avyxa), 1 mg
- C9309 — Injection, onasemnogene abeparvovec-brve, per treatment
- C9310 — Injection, leucovorin calcium (avyxa), 1 mg
- C9311 — Injection, eplontersen, 1 mg (code may be used for medicare when drug administered under the direct supervision of a physician, not for use when drug is self administered)
- C9312 — Injection, trabectedin (apotex), not therapeutically equivalent to j9362, 0.01 mg
Building a device that would bill under a code like this? Caduvo matches a device description to HCPCS/CPT codes, Medicare coverage and payment, and the FDA pathway in one report.
Next steps
- Run a reimbursement report for a device billed under C9300
- Watch C9300 for fee, coverage and descriptor changes
- Build a full Medicare revenue model for C9300
Compiled by Caduvo from public CMS (Medicare) records, HCPCS release October 2026. Fees are Medicare allowables, not commercial rates. Not reviewed or endorsed by CMS. Not billing or legal advice. Report an error. Data and corrections policy.